Tags: Drug.
Denosumab is a fully human monoclonal antibody for the treatment of osteoporosis treatment-induced bone loss bone metastases multiple myeloma and giant cell tumor of bone. It was developed by the biotechnology company Amgen.Denosumab is designed to inhibit RANKL (RANK ligand) a protein that acts as the primary signal for bone removal. In many bone loss conditions RANKL overwhelms the body’s natural defenses against bone destruction.In June 2010 denosumab was approved by the U.S.